Disease/Infection News

RSS

Interferon-free treatment for genotype-1b hepatitis C patients: an interview with Professor Wulf Boecher, Boehringer Ingelheim

Genotype 1 is, worldwide, the most prevalent genotype of the hepatitis C virus. It accounts for around seventy percent of all hepatitis C infections.

30 Jul 2013

Hope for treatment of childhood infections may come straight from the gut: Therapeutic poop

Call it therapeutic poop, if you will, but the best hope yet for an effective treatment of childhood infections with the drug-resistant bacterium C. difficile may come straight from the gut, according to recent research.

30 Jul 2013

Genistein derived from soybeans shows promise in inhibiting HIV infection

A compound found in soybeans may become an effective HIV treatment without the drug resistance issues faced by current therapies, according to new research by George Mason University researchers.

30 Jul 2013

FDA approves Rebiotix's IND application to begin RBX2660 Phase 2 study for recurrent CDI

Rebiotix Inc. announced today that the U.S. Food and Drug Administration has approved the company's Investigational New Drug application to begin the Phase 2 clinical study of RBX2660 for the treatment of recurrent Clostridium difficile infection.

30 Jul 2013

Anacor Pharmaceuticals submits tavaborole NDA to FDA for treatment of onychomycosis

Anacor Pharmaceuticals announced today that on July 26, 2013 it submitted its New Drug Application to the U.S. Food and Drug Administration for tavaborole, its drug candidate for the topical treatment of onychomycosis. Onychomycosis is a fungal infection of the nail and nail bed that affects approximately 35 million people in the United States.

30 Jul 2013

Hepatitis C (HCV) testing for baby boomers: an interview with Dr. Donald Jensen, Director, Center for Liver Diseases, University of Chicago

The USPSTF agreed with the CDC that since most patients (75%) who are currently infected with hepatitis C were born between 1945 - 1965, and since risk-based screening has not been successful in identifying these individuals, that a one time age-based hepatitis C blood test was necessary.

29 Jul 2013

Saudi and UK scientists provide detailed picture of MERS coronavirus

Saudi and UK scientists provide the most detailed picture yet of the clinical and laboratory characteristics of Middle East Respiratory Syndrome (MERS) coronavirus, revealing a wide range of clinical symptoms and an extremely high death rate among patients with co-existing medical conditions.

29 Jul 2013

World Hepatitis Alliance calls for urgent action to address viral hepatitis

On World Hepatitis Day, the World Hepatitis Alliance has called for urgent attention to be given to recent figures showing that although viral hepatitis kills as many as HIV/AIDS, the great majority of countries have no programmes in place to tackle it.

29 Jul 2013

Hepatocytes from stem-cell derived human liver cells increase survival of animals with liver disease

Researchers have generated functional hepatocytes from human stem cells, transplanted them into mice with acute liver injury, and shown the ability of these stem-cell derived human liver cells to function normally and increase survival of the treated animals.

29 Jul 2013

CHMP gives positive opinion for approval of once-daily QVA149 for treatment of COPD

Sosei Group Corporation confirms the information released by Novartis that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for approval of once-daily Ultibro® Breezhaler®, as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).

29 Jul 2013

GlaxoSmithKline receives CHMP positive opinion for REVOLADE

Ligand Pharmaceuticals Incorporated partner GlaxoSmithKline announced that today, the European Medicines Agency's Committee for Medicinal Products for Human Use issued a positive opinion recommending marketing authorization for GSK's REVOLADE (eltrombopag) as a treatment for low platelet counts (thrombocytopenia) in adult patients with chronic hepatitis C infection, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy

26 Jul 2013

Viewpoints: Doctors' sway over Medicare pay; hospital rankings not all they seem; legal immigrants' health needs overlooked

Reporters Peter Whoriskey and Dan Keating have opened Post readers' eyes to the fact that Medicare pays for physician services -; a $69.6 billion item in 2012 -; according to an arcane and little-known price list, over which doctors themselves exercise considerable and less-than-totally-transparent influence (7/24).

26 Jul 2013

WHO issues travel advice on MERS-CoV for pilgrims traveling to Kingdom of Saudi Arabia

The World Health Organization has issued interim travel advice on the Middle East respiratory syndrome coronavirus (MERS-CoV), which has affected nine countries to date.

26 Jul 2013

New species of adenovirus can spread from monkey to human, say researchers

Adenoviruses commonly infect humans, causing colds, flu-like symptoms and sometimes even death, but now UC San Francisco researchers have discovered that a new species of adenovirus can spread from primate to primate, and potentially from monkey to human.

26 Jul 2013

Miriam researcher calls for new strategies to better manage, improve treatment for HCV infection

A Miriam Hospital researcher has joined forces with international colleagues to call for new strategies to better manage and improve assessment and treatment for hepatitis C (HCV) infection in individuals who inject drugs.

26 Jul 2013

Zydus, IDRI partner to develop visceral leishmaniasis vaccine candidate

In a unique partnership, Zydus, India's fourth largest healthcare group and an innovation-led global healthcare provider, and IDRI, a Seattle-based non-profit research and product development organization, announced today they are collaborating on the production and clinical development of IDRI's visceral leishmaniasis vaccine candidate, designed to prevent the deadly parasitic disease.

26 Jul 2013

FDA allows marketing of Xpert MTB/RIF Assay for treatment of TB

The U.S. Food and Drug Administration today allowed marketing of the Xpert MTB/RIF Assay, the first FDA-reviewed test that can simultaneously detect bacteria that cause tuberculosis and determine if the bacteria contain genetic markers that makes them resistant to rifampin, an important antibiotic for the treatment of TB.

26 Jul 2013

First lots of 2013-2014 seasonal influenza vaccine released for U.S. distribution

Sanofi Pasteur, the vaccines division of Sanofi, announced today that the first lots of Fluzone (Influenza Virus Vaccine) for the 2013-2014 season have been released by the U.S. Food and Drug Administration for U.S. distribution and were shipped July 24.

25 Jul 2013

Report shows 2824 new cases of hantavirus disease in Germany in 2012

2824 new cases of hantavirus disease were reported in Germany in 2012, the highest number ever in a single year. In the current issue of Deutsches -rzteblatt International, Detlev Kr-ger and coauthors present the main facts about this disease (Dtsch Arztebl Int 2013; 110[27-28]: 461-7).

25 Jul 2013

Forced-air patient warming systems may affect airflows in OR; increase exposure to airborne contaminants

Forced-air systems used to keep patients warm during surgery may affect the performance of operating room (OR) ventilation systems-potentially increasing exposure to airborne contaminants, reports a study in the August issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).

25 Jul 2013

Disease/Infection News

Interferon-free treatment for genotype-1b hepatitis C patients: an interview with Professor Wulf Boecher, Boehringer Ingelheim

Hope for treatment of childhood infections may come straight from the gut: Therapeutic poop

Genistein derived from soybeans shows promise in inhibiting HIV infection

FDA approves Rebiotix's IND application to begin RBX2660 Phase 2 study for recurrent CDI

Anacor Pharmaceuticals submits tavaborole NDA to FDA for treatment of onychomycosis

Hepatitis C (HCV) testing for baby boomers: an interview with Dr. Donald Jensen, Director, Center for Liver Diseases, University of Chicago

Saudi and UK scientists provide detailed picture of MERS coronavirus

World Hepatitis Alliance calls for urgent action to address viral hepatitis

Hepatocytes from stem-cell derived human liver cells increase survival of animals with liver disease

CHMP gives positive opinion for approval of once-daily QVA149 for treatment of COPD

GlaxoSmithKline receives CHMP positive opinion for REVOLADE

Viewpoints: Doctors' sway over Medicare pay; hospital rankings not all they seem; legal immigrants' health needs overlooked

WHO issues travel advice on MERS-CoV for pilgrims traveling to Kingdom of Saudi Arabia

New species of adenovirus can spread from monkey to human, say researchers

Miriam researcher calls for new strategies to better manage, improve treatment for HCV infection

Zydus, IDRI partner to develop visceral leishmaniasis vaccine candidate

FDA allows marketing of Xpert MTB/RIF Assay for treatment of TB

First lots of 2013-2014 seasonal influenza vaccine released for U.S. distribution

Report shows 2824 new cases of hantavirus disease in Germany in 2012

Forced-air patient warming systems may affect airflows in OR; increase exposure to airborne contaminants

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News